# 약물 특성 (Drug-likeness)
*1.4 pdf 참고

### **Drug-like compound**

Drug : ill-defined entity from a chemical standpoint

“**acceptable ADME/Tox” properties**를 가진 compounds

⇒ human Phase 1(임상 1상) trials에서 생존.

- **[Lipinski’s Rule-of-5] : 전통적으로 사용되는 Drug-likeness 지표**
    
    ![5state](https://github.com/doammii/CADD-study/assets/100724454/e7f2c770-6225-49b0-9707-4480e94a6589)
    

Increases : three of the four rule-of-five properties (molecular mass / O plus N atom count / OH plus NH count)

### PD/PK

- PD : Drug → Biological system / Bioactivity, Toxicity
- PK : Biological system → Drug / ADME

![comparison](https://github.com/doammii/CADD-study/assets/100724454/4715b07f-e5b4-44ad-8970-8f3411583b1e)

### Lipophilicity

### QED(Quantiative Estimate of Drug-likeness)

*Quantifying the chemical beauty of drugs*

Combining the **individual desirability functions** → QED

- Performance : **RoC** (Receiver Operating Characteristic)
    
    QED는 Ro5를 정량적으로 표시 & 다른 거에 비해 DrugStore 경향을 잘 반영.
    

**“Lead-Like” libraries** : should be designed with lower MW(≤300) and lower logP(≤3.0) cutoffs

### SAS(Synthetic Accessibility Score)

**낮을수록** good. 몇 단계의 합성 과정을 거쳐야하는지?

논문 참고 : *Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions*(Etrl)

SAscore = fragmentScore - complexityPenalty